Suppr超能文献

核苷(酸)类似物治疗谷丙转氨酶正常且乙肝病毒脱氧核糖核酸水平高的HBeAg阳性慢性乙型肝炎的疗效研究

[A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].

作者信息

Wang F D, Zhou J, Zhang D M, Wang M L, Tao Y C, Wu D B, Tang H, Chen E Q

机构信息

Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2022 Apr 20;30(4):389-394. doi: 10.3760/cma.j.cn501113-20210705-00318.

Abstract

To investigate the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg-positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA. Treatment-naïve chronic hepatitis B patients who were followed up at the Center of Infectious Diseases, West China Hospital of Sichuan University from January 2019 to January 2020 were selected as subjects. Demographic characteristics, the results of laboratory examination before treatment and one year after treatment were retrospectively collected. Patients were divided into tenofovir dipivoxil (TDF) and propofol fumurate tenofovir (TAF) treatment group according to different types of medication. The changes of serum HBV DNA level, HBeAg serological conversion and HBsAg quantitative level were analyzed and compared between the two groups. A total of 38 cases were enrolled. Among them, there were 16 and 22 cases in the TDF and TAF group, respectively. There was no statistically significant difference in demographic characteristics, baseline HBV DNA levels and HBsAg quantitative levels between the two groups. Virological response was achieved in 60.5% (23/38) of patients after one year of antiviral therapy. Serum HBV DNA levels below the lower limit of detection [68.2% (15/22) . 50.0% (8/16), =0.258] and higher HBeAg seroconversion rate [18.2%] (4/22) . 6.3% (1/16), =0.374] was obtained in TAF than TDF group; however, there was no statistically significant differences between the two. Serum HBsAg quantitative level was significantly reduced with TDF and TAF treatment. In addition, alanine aminotransferase elevation was reduced in TAF than TDF treated group. Multivariate logistic regression analysis showed that patient age was an independent predictor of a virological response to antiviral therapy. HBeAg-positive CHB patients with normal alanine aminotransferase, and high HBV DNA level can obtain better curative effect after TDF and TAF treatment.

摘要

探讨核苷(酸)类似物治疗谷丙转氨酶正常但乙肝病毒脱氧核糖核酸(HBV DNA)水平高的HBeAg阳性慢性乙型肝炎的疗效。选取2019年1月至2020年1月在四川大学华西医院传染病中心进行随访的初治慢性乙型肝炎患者作为研究对象。回顾性收集患者的人口统计学特征、治疗前及治疗1年后的实验室检查结果。根据用药类型将患者分为替诺福韦酯(TDF)组和丙酚替诺福韦(TAF)组。分析比较两组血清HBV DNA水平、HBeAg血清学转换及HBsAg定量水平的变化。共纳入38例患者。其中,TDF组16例,TAF组22例。两组患者的人口统计学特征、基线HBV DNA水平及HBsAg定量水平差异均无统计学意义。抗病毒治疗1年后,60.5%(23/38)的患者获得病毒学应答。TAF组血清HBV DNA水平低于检测下限的比例[68.2%(15/22)]高于TDF组[50.0%(8/16),P=0.258],HBeAg血清学转换率[18.2%(4/22)]也高于TDF组[6.3%(1/16),P=0.374];但两组差异均无统计学意义。TDF和TAF治疗后血清HBsAg定量水平均显著降低。此外,TAF组谷丙转氨酶升高幅度低于TDF组。多因素logistic回归分析显示,患者年龄是抗病毒治疗病毒学应答的独立预测因素。谷丙转氨酶正常、HBV DNA水平高的HBeAg阳性慢性乙型肝炎患者经TDF和TAF治疗后可获得较好疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验